Key Takeaways ALNY posted Q2 earnings of $0.32 per share, reversing a loss, on strong Amvuttra-driven revenue growth.Amvuttra sales more than doubled to$492M, aided by expanded label use and patient switches from Onpattro.Alnylam raised 2025 product revenue guidance to $2.65-$2.8B, up from its prior range of $2.05-$2.25B.Alnylam Pharmaceuticals, Inc. (ALNY) reported second-quarter 2025 earnings of 32 cents per share, in contrast to the Zacks Consensus Estimate of a loss of 3 cents. The improvement was due ...